Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.…
How FDA Review Acceptance At Celcuity (CELC) Has Changed Its Investment Story
Celcuity (NASDAQ: CELC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 155 employees.
The shares were at 53.35 USD on 20 November 2026, down 28.4% over 52 weeks. Its 52-week range is 53.20 USD to 151.02 USD, and it trades at the bottom of that range.
Its market capitalisation is 2.61B USD.
Celcuity reports return on equity of -176.1% and an operating margin of 0.0%.
Its debt exceeds its cash by 112.36M USD, a debt-to-equity ratio of 3.20. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 150.85 USD is 182.7% above the current price. The next earnings report is expected on 24 March 2027.